Trade HALO stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Halozyme Therapeutics, Inc. (HALO) is trading at US$107.00, down 0.36% today as of Sep 10, 16:00 EDT. The company has a market capitalisation of US$12.28B. Over the past 52 weeks, HALO has traded between US$61.23 and US$111.15. On Syfe you can trade HALO with $0 commission and add it to your watchlist.
| Previous close | US$107.39 |
|---|---|
| Market cap | US$12.28B |
| P/E ratio | 11.01 |
| 52-week range | US$61.23 – US$111.15 |
| Volume | 1.31M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Year: 2004
Morgan Stanley Adjusts PT on Halozyme Therapeutics to $105 From $93, Maintains Overweight Rating
Aug 7, 9:29 AM · MT Newswires
Halozyme Therapeutics Q2 Adjusted Earnings, Revenue Rise; Shares Gain After Hours
Aug 6, 8:33 PM · MT Newswires
-- GUIDANCE: (HALO) Halozyme Therapeutics Now Expects 2026 Adjusted EPS Range $8.65-$9.00, vs. FactSet Est of $7.94
Aug 6, 8:27 PM · MT Newswires
-- GUIDANCE: (HALO) Halozyme Therapeutics Now Expects 2026 Revenue Range $1.835B-$1.910B, vs. FactSet Est of $1.77B
Aug 6, 8:26 PM · MT Newswires
Halozyme Therapeutics, Inc. (HALO) stock is trading at US$107.00, -0.36% from the previous close of US$107.39.
The market cap for Halozyme Therapeutics, Inc. (HALO) stock is approximately US$12.28B.
The price-to-earnings ratio for Halozyme Therapeutics, Inc. (HALO) is 11.01, based on the latest reported earnings.
The 52-week high for Halozyme Therapeutics, Inc. (HALO) stock is US$111.15.
The 52-week low for Halozyme Therapeutics, Inc. (HALO) stock is US$61.23.
Halozyme Therapeutics, Inc. (HALO) does not currently pay a dividend.
Stay on top of HALO
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
